Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.
Patel SA, Goyal S, Liu Y, Moghanaki D, Patel PR, Hanasoge S, Dhere VR, Shelton JW, Godette KD, Jani AB, Hershatter B, Fischer-Valuck BW. Patel SA, et al. Among authors: goyal s. JAMA Netw Open. 2020 Dec 1;3(12):e2025143. doi: 10.1001/jamanetworkopen.2020.25143. JAMA Netw Open. 2020. PMID: 33301015 Free PMC article.
Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
Fischer-Valuck BW, Rao YJ, Brenneman RJ, Patel PR, Filson CP, Jani AB, Liu Y, Goyal S, Xu K, Weiss A, Kucuk O, Cimmino C, Szabo S, Rossi P, Baumann BC, Pattaras J, Hershatter B, Patel SA. Fischer-Valuck BW, et al. Among authors: goyal s. Brachytherapy. 2020 Sep-Oct;19(5):557-566. doi: 10.1016/j.brachy.2020.05.007. Epub 2020 Jul 3. Brachytherapy. 2020. PMID: 32624405
Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
Jani A, Schreibmann E, Goyal S, Raghuveer H, Hershatter B, Rossi PJ, Shelton JW, Patel PR, Xu KM, Goodman M, Master V, Joshi SS, Kucuk O, Carthon B, Bilen MA, Cooper S, Fielder B, Abiodun-Ojo O, Dhere VR, Schuster DM. Jani A, et al. Among authors: goyal s. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1397. doi: 10.1016/j.ijrobp.2020.09.018. Epub 2020 Nov 18. Int J Radiat Oncol Biol Phys. 2020. PMID: 33427655 No abstract available.
Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance.
Abiodun-Ojo OA, Jani AB, Akintayo AA, Akin-Akintayo OO, Odewole OA, Tade FI, Joshi SS, Master VA, Fielder B, Halkar RK, Zhang C, Goyal S, Goodman MM, Schuster DM. Abiodun-Ojo OA, et al. Among authors: goyal s. J Nucl Med. 2021 Aug 1;62(8):1089-1096. doi: 10.2967/jnumed.120.256784. Epub 2021 Jan 30. J Nucl Med. 2021. PMID: 33517323 Free PMC article.
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ, Shelton JW, Patel PR, Xu KM, Goodman M, Master VA, Joshi SS, Kucuk O, Carthon BC, Bilen MA, Abiodun-Ojo OA, Akintayo AA, Dhere VR, Schuster DM. Jani AB, et al. Among authors: goyal s. Lancet. 2021 May 22;397(10288):1895-1904. doi: 10.1016/S0140-6736(21)00581-X. Epub 2021 May 7. Lancet. 2021. PMID: 33971152 Free PMC article. Clinical Trial.
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ, Goyal S, Liu Y, Evans ST, Olsen TA, Case K, Magod BL, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Nazha B, Harris WB, Kissick HT, Master VA, Kucuk O, Carthon BC, Bilen MA. Martini DJ, et al. Among authors: goyal s. Oncologist. 2021 Oct;26(10):e1742-e1750. doi: 10.1002/onco.13868. Epub 2021 Jul 8. Oncologist. 2021. PMID: 34156726 Free PMC article.
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.
Olsen TA, Martini DJ, Goyal S, Liu Y, Evans ST, Magod B, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Harris WB, Kucuk O, Carthon BC, Master VA, Nazha B, Bilen MA. Olsen TA, et al. Among authors: goyal s. Front Oncol. 2021 Jun 16;11:701345. doi: 10.3389/fonc.2021.701345. eCollection 2021. Front Oncol. 2021. PMID: 34222024 Free PMC article.
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
Martini DJ, Olsen TA, Goyal S, Liu Y, Evans ST, Magod B, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Nazha B, Kissick HT, Harris WB, Kucuk O, Carthon BC, Master VA, Bilen MA. Martini DJ, et al. Among authors: goyal s. Front Oncol. 2021 Jul 9;11:707050. doi: 10.3389/fonc.2021.707050. eCollection 2021. Front Oncol. 2021. PMID: 34307176 Free PMC article.
2,152 results